Bradley Shoss, MD
Ophthalmology · Titusville, FLNPI 1013203272
Payments from drug & device makers
Across 105 payments — averaging $40.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$583
- Glaukos Corporation$534
- Bausch & Lomb, A Division Of Bausch Health US, LLC$324
- Rxsight Inc$215
- Dompe US, Inc.$204
- plus $989 from 13 others
What the payments were for
- Food & beverage$4,256100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 24 | $1,425 |
| AbbVie(2 entities) | 23 | $583 |
| Glaukos Corporation | 8 | $534 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $324 |
| Rxsight Inc | 2 | $215 |
| Dompe US, Inc. | 7 | $204 |
| Rayner Intraocular Lenses Limited | 5 | $197 |
| Harrow Eye, LLC | 6 | $160 |
| Regeneron Healthcare Solutions, Inc. | 1 | $117 |
| Oyster Point Pharma, Inc. | 5 | $106 |
| Tarsus Pharmaceuticals, Inc. | 4 | $96 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $93 |
| Amgen(2 entities) | 4 | $70 |
| Novartis | 2 | $42 |
| Bausch & Lomb Americas Inc. | 2 | $38 |
| Aerie Pharmaceuticals, Inc. | 2 | $27 |
| Shire North American Group Inc | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $14 |
| Biotissue Holdings Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Centurion$384
- ENVISTA$216
- Clareon$131
- AcrySof$130
- LUMIGAN$125
- ALPHAGAN P$125
- RayOne EMV$124
- RayOne Spheric$124
- RayOne Aspheric$124
- CE-marked KXLA system$119
- EYLEA$117
- KXL System$113
- Photrexa$113
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$113
- RXSIGHT CONTACT LENS$101
- RXSIGHT INJECTOR CARTRIDGE$101
- RXSIGHT INJECTOR HANDPIECE$101
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$101
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$101
How this compares
$4,273 in reported general payments places this provider in the 65th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $340,673 |
| XiidraLifitegrast | 39 | $35,379 |
| RestasisCyclosporine | 32 | $33,164 |
| LumiganBimatoprost | 70 | $30,976 |
| Prednisolone Acetate | 390 | $14,230 |
| Loteprednol Etabonate | 52 | $13,958 |
| Ketorolac Tromethamine | 147 | $7,518 |
| RocklatanNetarsudil Mesylat/Latanoprost | 19 | $6,592 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $6,294 |
| ValacyclovirValacyclovir Hcl | 97 | $5,099 |
| Travoprost | 28 | $4,553 |
| Latanoprost | 447 | $4,507 |
| Famciclovir | 11 | $3,795 |
| Ofloxacin | 179 | $3,605 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 18 | $3,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $204 | $340,67312 claims |
| AbbVieRestasis, Lumigan, Combigan | $583 | $70,433118 claims |
| Bausch & Lomb Americas Inc.Xiidra | $38 | $35,37939 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $324 | $13,95852 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $27 | $6,59219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Titusville
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.